Stanley T. Crooke
Papers
1
Total Citations
350
H-Index
1
About
Stanley T. Crooke is a pioneering figure in nucleic acid therapeutics, whose foundational work has profoundly shaped the field of antisense technology. His research primarily focuses on the molecular pharmacology of antisense oligonucleotides, with a key emphasis on understanding the mechanisms of RNA degradation. Crooke’s major contribution was definitively establishing the role of human RNase H1 in the pharmacology of DNA-like antisense drugs. His landmark 2004 paper, cited over 350 times, provided the first conclusive evidence that RNase H1 is the critical enzyme responsible for cleaving target RNA when bound by antisense oligonucleotides, thereby validating a core mechanism of action for an entire class of drugs. Beyond this mechanistic breakthrough, Crooke has been instrumental in translating these discoveries into clinical applications, advancing therapies for cancer, inflammatory diseases, and genetic disorders. As the founder and CEO of Ionis Pharmaceuticals, he has overseen the development of multiple FDA-approved antisense drugs. With a career spanning decades and thousands of citations, Crooke is widely recognized as a visionary who turned a theoretical concept into a transformative therapeutic platform.
Research Focus
Key Achievements
Top Papers
- 1